Form 4: Aileron Therapeutics Director Alan Musso Acquires 35,000 Stock Options

Aileron Therapeutics director Alan Musso was granted 35,000 stock options on December 2, 2024, which will vest on December 2, 2025.

Summary

• Alan Musso, a director at Aileron Therapeutics, was granted 35,000 stock options on December 2, 2024.
• The exercise price of these options is $2.85 per share.
• The options will vest in full on December 2, 2025.
• The options expire on December 1, 2034.

Sentiment

Score: 6

Explanation: The document is a routine filing related to stock option grants, which is generally neutral. It indicates alignment of interests between the director and shareholders.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders.
• The vesting period of one year may encourage the director to focus on long-term value creation.

Industry Context

Stock option grants are a common form of compensation for directors and executives in publicly traded companies, aligning their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard practice for compensating directors in the biotechnology industry.
• The vesting period of one year is typical for such grants, encouraging long-term focus.
• The exercise price of $2.85 is a specific value for this grant and would need to be compared to other grants to determine if it is standard.

Stakeholder Impact

• The stock option grant may be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.

Key Dates

Keywords

stock options, director, Aileron Therapeutics, ALRN, insider trading, equity compensation, vesting